FDA clears Biosonix' noninvasive blood flow device:
This article was originally published in Clinica
Neoprobe's subsidiary Biosonix has gained the green light in the US to market its FlowGuard system for measuring blood flow in noninvasive diagnostic and intraoperative applications. The device uses digital ultrasound technology to provide accurate measurements of blood flow in real-time and is substantially less invasive and more specific than alternative methods, claimes Neoprobe, of Dublin, Ohio. The system is expected to be of particular use to neurosurgeons and vascular surgeons assessing flow volume in major blood vessels and arteries. In a separate announcement, Biosonix says that it is to change its name to Cardiosonix.